Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES

The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment (EoT) when patients have sustained virological response 12 weeks post treatment. BL=baseline

Time frame: End of treatment, up to 48 weeks

ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO

The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline

Time frame: 12 weeks post treatment, up to 60 weeks

ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES

The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline

Time frame: 12 weeks post treatment, up to 60 weeks

AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO

The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline

Time frame: 12 weeks post treatment, up to 60 weeks

AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES

The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline

Time frame: 12 weeks post treatment, up to 60 weeks